Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Stock analysts at Wedbush increased their FY2022 EPS estimates for Zentalis Pharmaceuticals in a research note issued to investors on Monday, November 14th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($4.46) per share for the year, up from their prior estimate of ($4.73). Wedbush has a “Outperform” rating and a $32.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($4.67) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2022 earnings at ($0.97) EPS, FY2023 earnings at ($4.13) EPS, FY2024 earnings at ($4.35) EPS, FY2025 earnings at ($2.93) EPS and FY2026 earnings at $0.54 EPS.
Several other research firms have also recently weighed in on ZNTL. HC Wainwright reduced their target price on shares of Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $55.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, November 11th. SVB Leerink reduced their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 10th. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a report on Monday. Finally, Oppenheimer lowered their target price on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, November 10th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $45.88.
Zentalis Pharmaceuticals Price Performance
Institutional Investors Weigh In On Zentalis Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. Captrust Financial Advisors grew its stake in Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares in the last quarter. Assetmark Inc. boosted its stake in Zentalis Pharmaceuticals by 337.3% during the second quarter. Assetmark Inc. now owns 1,054 shares of the company’s stock worth $30,000 after acquiring an additional 813 shares in the last quarter. US Bancorp DE grew its stake in shares of Zentalis Pharmaceuticals by 378.9% in the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after acquiring an additional 1,148 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at $72,000. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at about $48,000.
Insider Buying and Selling at Zentalis Pharmaceuticals
In related news, President Cam Gallagher sold 12,500 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $22.32, for a total transaction of $279,000.00. Following the sale, the president now owns 431,885 shares of the company’s stock, valued at $9,639,673.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 62,500 shares of company stock worth $1,469,125 over the last 90 days. Company insiders own 19.90% of the company’s stock.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Use The Airbnb Stock Implosion to Your Advantage
- International Game Technology is Well Worth the Gamble
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.